93 results about "Oncology drug" patented technology

The invention relates to a new application of sodium-potassium ATP enzyme inhibitor uabain for reversing tolerance of cells of non-small cell lung cancer (NSCLC) to targeted anti-tumor drugs. Particularly, the uabain can be used as a sensitizer for treating the NSCLC and is combined with TRAIL to be used for treating the NSCLC.

The invention discloses an application of combined utilization of triptolide cisplatin in preparation of a pancreatic cancer drug against drug resistance. Experiments on two drug-resistant pancreatic cancer cells PANC-1 and MIAPaCa-2 and nude mice with inoculated with PANC-1 cells on flanks prove that the effects of synergistic tumor inhibition can be achieved for drug-resistant pancreatic cancer through the combined utilization of triptolide cisplatin. So far, no study on the synergistic inhibition of the pancreatic cancer through the combined utilization of triptolide cisplatin is reported. In the nude mouse xenografting model, the tumor growth can be significantly inhibited through the combined utilization of low doses of triptolide and cisplatin, and cannot be inhibited when only the triptolide or cisplatin is used. The results of immunohistochemistry for each group of tumor biopsies show that the HSP27 protein expression can be reduced significantly through the combined utilization of the two drugs, and the results are identical to the results on cell lines. Therefore, the triptolide and cisplatin can be used together as a sensitizing agent of anticancer drugs.

The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors. Examples of specific tumor types that the compounds may be used to treat include, but are not limited to sarcomas, melanomas, neuroblastomas, carcinomas (including but not limited to lung, renal cell, ovarian, liver, bladder, and pancreatic carcinomas), and mesotheliomas.

The invention relates to disubstituted phenyl biguanide compounds and application containing the same to inducing malignant tumor cell for anoikis and inhibiting tumor growth and transfer. Proved by in vitro-in vivo experiments, the disubstituted phenyl biguanide compounds show the remarkable functions of inducing the malignant tumor cell for anoikis, starting caspase cascade and inhibiting tumor growth and transfer and also have the characteristics of high efficiency and low toxicity, so the disubstituted phenyl biguanide compounds as pharmaceutical compounds are expected to be applied to a plurality of malignant tumor medicaments for inhibiting the tumor growth, invasion and metastasis and treating human melanoma, neurospongioma, lung cancer, gastric cancer, prostate cancer, ovarian cancer and the like.

The present invention is the application of acetyl boswellic acid (BC-4) extracted from Boswellia carterii Birdw as antitumor medicine, a secondary application. It is found that BC-4 has the functions of resisting the proliferation of tumor cell, inducing malignant tumor cell to death, inhibiting the proliferation of human umbilical vein endothelial cell, inhibiting animal's grafted tumor, inhibiting metastasis of malignant tumor, etc. Both in vivo and vitro tests show that BC-4 has very low toxicity and is one excellent antitumor medicine and tumor metastasis inhibitor.

An application of the Japanese butterbur's extract (bakkenolide D, B, IVa and IIIa) in preparing the medicines for preventing and treating liver cancer, lung cancer, cervical cancer, intestinal cancer, kidney cancer, bread cancer, etc is disclosed.

The present invention discloses a class of deuterated 3-(4,5-substituted aminopyrimidine) phenyl derivatives and applications thereof, which are compounds having the structure of formula (I) or pharmaceutically acceptable salts thereof, these compounds or their Salts can be used for the treatment or prevention of diseases or conditions through certain mutant forms of epidermal growth factor receptors, can effectively inhibit the growth of various tumor cells, and have inhibitory effects on EGFR, other proteases of the Her family, and can be used in the preparation of anti-inflammatory drugs. Oncology drugs.

The invention discloses the use of PD-0332991 in the preparation of drugs for preventing and treating drug-resistant tumors. The present invention uses cell biology and molecular biology methods, as well as tests on human gefitinib-resistant nude mouse xenograft tumor models to prove that PD‑0332991 can effectively inhibit the growth of human gefitinib-resistant lung cancer cells and induce apoptosis. Regulates cell cycle-related genes, causes tumor cell cycle arrest, and induces apoptosis. Therefore, PD‑0332991 can be used as an active ingredient to prepare drugs for preventing and treating gefitinib-resistant tumors, as well as foods, health products and cosmetics for preventing and treating drug-resistant tumors.

The invention provides a use of a gene GADD45 beta in preparation of drugs for treating cancers and especially provides a use of the gene GADD45 beta in preparation of a drug for treating bladder cancer. According to the invention, an over-expression vector of the gene GADD45 beta is constructed and is transferred into tumor cells. A result shows that an mRNA level of the tumor cells with the gene GADD45 beta is improved obviously; roundness of the tumor cells is improved and adherence of the tumor cells is reduced; and tumor cell activity is improved obviously by 85% and tumor cells die finally. The gene GADD45 beta has high tumor cell inhibition activity and provides base data for novel drug target discovery and a tumor-treatment drug design.

The invention relates to the technical field of medicines, in particular to application of apatinib to preparing BRAF V600E protein kinase inhibitors and application of the apatinib to preparing medicines for treating BRAF V600E mutation tumor. Melanoma, thyroid papillary carcinoma, borderline ovarian tumor, colorectal cancer, non-small cell lung cancer and hairy cell leukemia can be treated by the medicines. The application has the advantages that novel targets and indication can be provided for the apatinib; novel thinking can be provided for treating tumor such as BRAF V600E mutation melanoma, colorectal cancer and non-small cell lung cancer.

The invention provides a glyoxalase I irreversible inhibitor shown as the formula I (pleases see the formula in the description) and a preparation method and application thereof. The glyoxalase I irreversible inhibitor reacts with glyoxalase I in a covalent bond mode to enable the glyoxalase I to be irreversibly inactivated. The glyoxalase I irreversible inhibitor has good application and development prospects on preparation of drugs for treating malignant tumors such as a prostatic cancer, a lung cancer, an intestinal cancer, a bladder cancer, leukemia, a breast cancer and a skin cancer and various relapsed tumors.

This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate when present as a single phosphate diastereoisomer and, in particular, it relates to the (S)-phosphate diastereoisomer which offers a remarkable and unexpected increase in solubility relative to the (R)-diastereoisomer. The (S)-phosphate epimer is also preferentially taken up into cyclodextrin solutions over the (R)-diastereoisomer.